Table 5. Surveyed Korean Gynecologic Oncology Group members' adjuvant therapy recommendations for completely staged endometrial cancer.
| Scenario | Stage II | Stage IA and positive cytology | Stage IIIC1 | Stage IIIA |
|---|---|---|---|---|
| Adjuvant therapy (%) | ||||
| Yes | 89.6 | 55.3 | 100 | 95.7 |
| No | 10.4 | 44.7 | 0 | 4.3 |
| If yes, preferred treatment (%) | ||||
| 1 | WPRT (31.8) | Chemotherapy (57.7) | CCRT (53.2) | Chemotherapy (42.0) |
| 2 | VB (29.4) | CCRT (17.3) | Chemotherapy (28.7) | CCRT (31.8) |
| 3 | WPRT+VB (21.2) | WPRT (13.5) | WPRT+VB (12.8) | WPRT (17.0) |
| 4 | CCRT (14.1) | Hormone therapy (7.7) | WPRT (5.3) | WPRT+VB (9.1) |
CCRT, concurrent chemoradiotherapy; VB, vaginal brachytherapy; WPRT, whole pelvic radiation therapy.